Promises and challenges of adoptive T-cell therapies for solid tumours

Area of Science:

• Oncology
• Immunology
• Genomics
• Cell Therapy Manufacturing

Background:

• Cancer remains a leading cause of death globally, with metastatic disease posing a significant challenge despite current therapies.
• Adoptive T-cell therapy, utilizing tumor-infiltrating lymphocytes or engineered T cells, shows promise for durable responses and potential cures in cancer patients.
• Advances in genomics, immunology, and cell manufacturing are driving the development of personalized cell-based therapeutics.

Purpose of the Study:

• To discuss the essential areas for translating T-cell therapies into effective treatments for solid malignancies.
• To highlight key advances in understanding tumor heterogeneity and neoantigen identification.
• To explore strategies for overcoming T-cell exhaustion and tumor immunosuppression.

Main Methods:

• Discussion of advances in cancer genomics for identifying neoantigens.
• Exploration of immunological strategies to combat T-cell exhaustion and tumor-induced immunosuppression.
• Review of cell manufacturing advancements for therapeutic applications.

Main Results:

• Progress in understanding genetic intratumour heterogeneity.
• Development of strategies for neoantigen identification and overcoming immune evasion.
• Advancements in cell manufacturing processes enhancing therapeutic potential.

Conclusions:

• T-cell therapies represent a paradigm shift in cancer treatment, particularly for solid tumors.
• Despite challenges, ongoing research in genomics, immunology, and manufacturing holds significant promise for improving patient outcomes.
• Personalized cell-based therapeutics are moving closer to clinical reality, offering new hope for advanced cancer patients.